Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navitoclax - AbbVie

Next Previous
Drug Profile

Navitoclax - AbbVie

Alternative Names: ABT-263; RG 7423; RG 7433

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Centre hospitalier de l'Universite de Montreal; Genentech; National Cancer Institute (USA); Princess Margaret Hospital (University of Toronto); Sunnybrook Health Sciences Centre
  • Class Antifibrotics; Antineoplastics; Benzamides; Morpholines; Piperazines; Senotherapeutics; Small molecules; Sulfones
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelofibrosis
  • Phase I/II Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Phase I Haematological malignancies; Ovarian cancer; Triple negative breast cancer
  • Preclinical Colorectal cancer; Head and neck cancer; Idiopathic pulmonary fibrosis; Vascular disorders
  • No development reported Crohn's disease
  • Discontinued Chronic lymphocytic leukaemia; Lymphoid leukaemia; Lymphoma; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in USA (PO, Tablet)
  • 18 Jan 2024 Efficay, adverse events and drug interaction data from a phase I trial in Solid tumours presented at the 2024 Gastrointestinal Cancers Symposium, 2024 (ASCO-GCS-2024)
  • 11 Dec 2023 Updated safety and efficacy data from a phase III TRANSFORM-1 trial in Myelofibrosis released by AbbVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top